Medically reviewed by Abhijit Bhattacharyya | MD, PhD, MBA, Tufts University School of Medicine - Miami, Florida on November 17th, 2025.
Important Note: Orforglipron is a weight loss pill that is not yet FDA-approved. Eli Lilly plans to submit for regulatory approval in late 2025, with potential approval expected in 2026.
For many people considering GLP-1 medications for weight loss, the biggest barrier isn't the cost or commitment—it's the needle. Injectable medications like Wegovy and Zepbound have proven remarkably effective, but not everyone is comfortable with weekly self-injections. That's where oral GLP-1 medications (weight loss pills) like orforglipron come into the picture.
The most obvious difference between weight loss shots and pills is administration. Injectable GLP-1s require weekly subcutaneous injections, typically in the abdomen, thigh, or upper arm. Orforglipron, by contrast, is a once-daily pill that can be taken any time of day without restrictions on food or water intake.
For people with needle phobia, busy travel schedules, or those who simply prefer oral medications, this difference could be transformative. There's no need for refrigeration or injection supplies, making the treatment more accessible and portable.
How does orforglipron stack up against injectable options in terms of actual weight loss? The results are encouraging. In the Phase 3 ATTAIN-1 trial, participants taking the highest dose of orforglipron lost an average of 12.4% of their body weight over 72 weeks.
For context, injectable semaglutide (Wegovy) typically produces weight loss of approximately 15% over a similar timeframe, while tirzepatide (Zepbound) can achieve around 20% weight loss. While orforglipron's weight loss appears somewhat lower than the newest injectable options, investigators have noted that its efficacy profile is consistent with the injectable GLP-1 class.
Based on clinical trial data, both oral and injectable GLP-1 medications share similar side effect profiles, as they work through the same mechanism. Gastrointestinal side effects are the most common, including:
Nausea
Diarrhea
Vomiting
Dyspepsia
Injectable GLP-1s typically require dose escalation over several weeks or months but then maintain a steady weekly schedule.
Orforglipron requires daily administration, which could be seen as either more convenient (no need to remember a specific injection day each week) or more burdensome (daily commitment) depending on individual preferences.
While pricing for orforglipron hasn't been announced, oral medications are generally less expensive to manufacture and distribute than biologics requiring cold storage.
The simplified distribution and storage of a small molecule drug could improve scalability, potentially making treatment available to more people who need it, especially in areas where cold chain storage is challenging.
Generally speaking, costs for GLP-1s vary depending on insurance coverage.
Consider injectable GLP-1s if you:
Want maximum weight loss efficacy
Prefer less frequent dosing (once weekly)
Don't mind self-injection
Consider oral options like orforglipron (when available) if you:
Have needle phobia or strong aversion to injections
Travel frequently and want simplified medication management
Prefer daily oral medication routines
Live in areas where medication storage is challenging
While orforglipron is not yet available, Doctronic can help you access FDA-approved weight loss medications today, including both injectable and oral options currently on the market. Our licensed healthcare providers will work with you to determine the best treatment approach for your individual needs and preferences.
Important Note: Orforglipron is a weight loss pill that is not yet FDA-approved. Eli Lilly plans to submit for regulatory approval in late 2025, with potential approval [...]
Read More
